245
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats

, , &
Pages 731-740 | Received 13 Jul 2010, Accepted 11 Jan 2011, Published online: 23 Mar 2011

References

  • Agu RU, Valiveti S, Earles DC, Klausner M, Hayden PJ, Wermeling DP, Stinchcomb AL. (2004). Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats. Endocr Res, 30, 455–467.
  • Agu RU, Valiveti S, Paudel KS, Klausner M, Hayden PJ, Stinchcomb AL. (2006). Permeation of WIN 55,212-2, a potent cannabinoid receptor agonist, across human tracheo-bronchial tissue in vitro and rat nasal epithelium in vivo. J Pharm Pharmacol, 58, 1459–1465.
  • Babu RJ, Dayal P, Singh M. (2008). Effect of cyclodextrins on the complexation and nasal permeation of melatonin. Drug Deliv, 15, 381–388.
  • Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. (2004). Intranasal insulin improves memory in humans. Psychoneuroendocrinology, 29, 1326–1334.
  • Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL, Born J, Kern W. (2007). Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology, 32, 239–243.
  • Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. (2002). Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci, 5, 514–516.
  • Cardinali DP, Vacas MI, Boyer EE. (1979). Specific binding of melatonin in bovine brain. Endocrinology, 105, 437–441.
  • Charlton ST, Davis SS, Illum L. (2007). Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterisation studies. J Control Release, 118, 225–234.
  • Chow HH, Anavy N, Villalobos A. (2001). Direct nose-brain transport of benzoylecgonine following intranasal administration in rats. J Pharm Sci, 90, 1729–1735.
  • Christrup LL. (1997). Morphine metabolites. Acta Anaesthesiol Scand, 41, 116–122.
  • Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. (2007). Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm, 337, 1–24.
  • Dahlin M, Bergman U, Jansson B, Björk E, Brittebo E. (2000). Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res, 17, 737–742.
  • Dayal P, Shaik MS, Singh M. (2004). Evaluation of different parameters that affect droplet-size distribution from nasal sprays using the Malvern Spraytec. J Pharm Sci, 93, 1725–1742.
  • de Lange EC, de Boer BA, Breimer DD. 1999. Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv Drug Deliv Rev, 36, 211–227.
  • DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr. (2000). The absolute bioavailability of oral melatonin. J Clin Pharmacol, 40, 781–784.
  • Dhuria SV, Hanson LR, Frey WH 2nd. (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci, 99, 1654–1673.
  • Dubey V, Mishra D, Jain NK. (2007). Melatonin loaded ethanolic liposomes: physicochemical characterization and enhanced transdermal delivery. Eur J Pharm Biopharm, 67, 398–405.
  • Fischer TW, Scholz G, Knöll B, Hipler UC, Elsner P. (2001). Melatonin reduces UV-induced reactive oxygen species in a dose-dependent manner in IL-3-stimulated leukocytes. J Pineal Res, 31, 39–45.
  • Frey I, William H. (2001). Method for Administering Insulin to the Brain. US patent application, US Patent 6313093.
  • Frey WH. (2002). Bypassing the blood-brain barrier to delivery therapeutic agents to the brain and spinal cord. Drug Del Tech 2, 46–49.
  • Graff CL, Pollack GM. (2005). Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci, 94, 1187–1195.
  • Graumlich JF, McLaughlin RG, Birkhahn D, Shah N, Burk A, Jobe PC, Dailey JW. (2000). Subcutaneous microdialysis in rats correlates with carbamazepine concentrations in plasma and brain. Epilepsy Res, 40, 25–32.
  • Gross EA, Swenberg JA, Fields S, Popp JA. (1982). Comparative morphometry of the nasal cavity in rats and mice. J Anat, 135, 83–88.
  • Hafner A, Lovric J, Voinovich D, Filipovic-Grcic J. (2009). Melatonin-loaded lecithin/chitosan nanoparticles: physicochemical characterisation and permeability through Caco-2 cell monolayers. Int J Pharm, 381, 205–213.
  • Hanson LR, Frey WH 2nd. (2008). Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci, 9 Suppl 3, S5.
  • Harris AS, Ohlin M, Lethagen S, Nilsson IM. (1988a). Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. J Pharm Sci, 77, 337–339.
  • Harris AS, Svensson E, Wagner ZG, Lethagen S, Nilsson IM. (1988b). Effect of viscosity on particle size, deposition, and clearance of nasal delivery systems containing desmopressin. J Pharm Sci, 77, 405–408.
  • Hayter CL, Bishop GM, Robinson SR. (2004). Pharmacological but not physiological concentrations of melatonin reduce iron-induced neuronal death in rat cerebral cortex. Neurosci Lett, 362, 182–184.
  • Illum L. (2003). Nasal drug delivery–possibilities, problems and solutions. J Control Release, 87, 187–198.
  • Jain R, Nabar S, Dandekar P, Patravale V. (2010). Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm Res, 27, 655–664.
  • Johnson NJ, Hanson LR, Frey WH. (2010). Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol Pharm, 7, 884–893.
  • Kanikkannan N, Andega S, Burton S, Babu RJ, Singh M. (2004). Formulation and in vitro evaluation of transdermal patches of melatonin. Drug Dev Ind Pharm, 30, 205–212.
  • Kararli TT, Needham TE, Schoenhard G, Baron DA, Schmidt RE, Katz B, Belonio B. (1992). Enhancement of nasal delivery of a renin inhibitor in the rat using emulsion formulations. Pharm Res, 9, 1024–1028.
  • Kaur C, Sivakumar V, Ling EA. (2008). Melatonin and its therapeutic potential in neuroprotection. Cent Nerv Syst Agents Med Chem, 8, 260–266.
  • Kreilgaard M. (2002). Assessment of cutaneous drug delivery using microdialysis. Adv Drug Deliv Rev, 54 Suppl 1, S99–121.
  • Lane EA, Moss HB. (1985). Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab, 61, 1214–1216.
  • Lewy AJ, Newsome DA. (1986). Different types of melatonin circadian secretary rhythms in some blind subjects. J Clin Endocrinol Metab, 56, 1103–1107.
  • Lindberger M, Tomson T, Ståhle L. (1998). Validation of microdialysis sampling for subcutaneous extracellular valproic acid in humans. Ther Drug Monit, 20, 358–362.
  • Mathy FX, Preat V, Verbeeck RK. (2001). Validation of subcutaneous microdialysis sampling for pharmacokinetic studies of flurbiprofen in the rat. J Pharm Sci, 90, 1897–1906.
  • Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, Cruz-Sanchez F, Chyan YJ, Smith MA, Perry G, Shoji M, Abe K, Leone A, Grundke-Ikbal I, Wilson GL, Ghiso J, Williams C, Refolo LM, Pappolla MA, Chain DG, Neria E. (2003). Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. J Neurochem, 85, 1101–1108.
  • Merkus P, Guchelaar HJ, Bosch DA, Merkus FW. (2003). Direct access of drugs to the human brain after intranasal drug administration? Neurology, 60, 1669–1671.
  • Morimoto K, Yamaguchi H, Iwakura Y, Morisaka K, Ohashi Y, Nakai Y. (1991). Effects of viscous hyaluronate-sodium solutions on the nasal absorption of vasopressin and an analogue. Pharm Res, 8, 471–474.
  • Pappolla MA, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B, Ghiso J. (1998). Inhibition of Alzheimer β-fibrillogenesis by melatonin. J Biol Chem, 273, 7185–7189.
  • Pappolla MA, Chyan YJ, Frangione BPB, Wilson G, Ghiso J, Reiter RJ. (2000). An assessment of the antioxidant and antiamyloidogenic properties of melatonin: implications for Alzheimer’s disease. J Neural Transm, 107, 203–231.
  • Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DLM, Reiter RJ, Efthimiopoulos S, Robakis NK. (1997). Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer’s amyloid peptide. J Neurosci, 17, 1683–1690.
  • Paul P, Lahaye C, Delagrange P, Nicolas JP, Canet E, Boutin JA. (1999). Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. J Pharmacol Exp Ther, 290, 334–340.
  • Picout DR, Ross-Murphy SB. (2003). Rheology of biopolymer solutions and gels. ScientificWorldJournal, 3, 105–121.
  • Priano L, Esposti D, Esposti R, Castagna G, De Medici C, Fraschini F, Gasco MR, Mauro A. (2007). Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J Nanosci Nanotechnol, 7, 3596–3601.
  • Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Ii WHF, Craft S. (2008a). Intranasal insulin administration dose dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis, 13, 323–331.
  • Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. (2008b). Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology, 70, 440–448.
  • Sánchez-Barceló EJ, Mediavilla MD, Tan DX, Reiter RJ. (2010). Clinical uses of melatonin: evaluation of human trials. Curr Med Chem, 17, 2070–2095.
  • Stenken JA, Lunte CE, Southard MZ, Ståhle L. (1997). Factors that influence microdialysis recovery. Comparison of experimental and theoretical microdialysis recoveries in rat liver. J Pharm Sci, 86, 958–966.
  • Vaka SR, Murthy SN. (2010). Enhancement of nose-brain delivery of therapeutic agents for treating neurodegenerative diseases using peppermint oil. Pharmazie, 65, 690–692.
  • van den Berg MP, Merkus P, Romeijn SG, Verhoef JC, Merkus FW. (2004). Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study. Pharm Res, 21, 799–802.
  • Wang X. (2009). The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther, 15, 345–357.
  • Wang Y, Aun R, Tse FL. (1998). Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm Drug Dispos, 19, 571–575.
  • Yamada K, Hasegawa M, Kametani S, Ito S. (2007). Nose-to-brain delivery of TS-002, prostaglandin D2 analogue. J Drug Target, 15, 59–66.
  • Yeleswaram K, McLaughlin LG, Knipe JO, Schabdach D. (1997). Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J Pineal Res, 22, 45–51.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.